Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.21 – $3.09
0% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $4.1M | $15.1M | $30.2M | $43.1M | $33.9M | $28.5M |
| Cost of revenue | $117.8K | $1.7M | $3.9M | $9.5M | $12.6M | $15.8M | $13.8M | $17.4M |
| Gross profit | −$117.8K | −$1.7M | $196.0K | $5.6M | $17.6M | $27.3M | $20.1M | $11.1M |
| Gross margin | — | — | 4.7% | 37.2% | 58.4% | 63.3% | 59.2% | 39.1% |
| R&D | $7.6M | $8.5M | $9.7M | $11.5M | $14.4M | $16.0M | $9.9M | $8.9M |
| Operating income | −$10.8M | −$26.5M | −$40.0M | −$52.8M | −$41.5M | −$26.5M | −$25.1M | −$39.6M |
| EBITDA | −$10.6M | −$25.8M | −$37.4M | −$31.4M | −$33.4M | −$35.8M | −$21.5M | −$34.9M |
| Net income | −$10.8M | −$27.5M | −$45.4M | −$48.3M | −$36.7M | −$41.0M | −$26.9M | −$39.3M |
| Net margin | — | — | -1098.1% | -318.9% | -121.5% | -95.1% | -79.5% | -137.6% |
| EPS (diluted) | -1.75 | -3.24 | -4.80 | -4.37 | -2.69 | -3.01 | -2.02 | -2.56 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $70M | $-1.41 | $-1.41–$-1.41 | 1 |
| 2027 | $89M | $-1.39 | $-1.39–$-1.39 | 1 |
| 2028 | $108M | $-1.37 | $-1.37–$-1.37 | 1 |
| 2029 | $11M | $-0.97 | $-0.97–$-0.97 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CASI.
No tracked institution reports a position in CASI as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-06-02 | 1-for-10reverse |
No one on the platform has traded CASI yet.
| $6M |
| — |
| ENTOEntero Therapeutics, Inc. | $2.85 | -5.00% | $14M | — |
| KAPAKairos Pharma, Ltd. | $0.36 | +2.00% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 2.0× historical median P/S.
Fair value ≈ $3.31 · price $0.21 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$DFNS time to bounce back with ither pennies $GPUS $CASI $WORX 🤔💪🔥🚀
View on StockTwits ↗$CASI next penny that likes to randomly spike 👉 $GPUS 🤔💪🚀
View on StockTwits ↗$CASI $CASIF at some point the market makers will run this to get the intitutional investors out Right now about 32% of the 19 million shares outstanding are held by institutions.
View on StockTwits ↗$CASI $CASIF where has everyone gone? This has a lot of potential
View on StockTwits ↗$CASI $CASIF average daily volume 1.1 Milion, lets get some volume here
View on StockTwits ↗$CASI $CASIF Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
View on StockTwits ↗$CASI now $CASIF .28 to .32 as this issue is way oversold
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.